实用临床医药杂志2011，Vol.15Issue(19)：43-45,3.
重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤的临床研究
The clinical research of endostar combined with chemotherapy on advanced malignancy
吕霞 1肖莉 1周启明 1王馨 1苏安 1吴炜新 1吴辉塔1
作者信息
- 1. 厦门大学附属中山医院肿瘤科,福建厦门,361004
- 折叠
摘要
Abstract
Objective To observe the clinical effect of recombinant human endostatin (en-dostar) combined with chemotherapy on advanced malignancy. Methods Fifty - one patients with advanced malignancy received endostar combined with chemotherapy. The dose of endostar was 7.5 mg/(m -d) by adding 500 mL normal saline intravenously, continuous administration for 14 days, rest 7 days, and 21 days as one cycle. The clinical effect and adverse reactions were observed. Results After two cycles, the clinical benefit rate of non~ small cell lung cancer (NSCLC) patients was 83.9% and the total clinical benefit rate was 80.4%. Up till to July, 2010, 18 cases survived and 33 cases died. Twelve cases with NSCLC survived, while 19 cases died. The median survival time was 14 months. The main adverse reaction was bone marrow suppression, 17 cases (33.3%) were degree Ⅲ - Ⅳ. The other adverse reactions were degree I or II. Conclusion Endostar combined with chemotherapy on advanced malignancy showed higher clinical benefit rate and longer lifetime, and the adverse reactions are tolerable. It's worth to be popularized and applied in clinical therapy.关键词
重组人血管内皮抑制素/化疗/晚期恶性肿瘤/临床研究Key words
recombinant human endostatin/ chemotherapy/ advanced malignancy/ clinical research分类
医药卫生引用本文复制引用
吕霞,肖莉,周启明,王馨,苏安,吴炜新,吴辉塔..重组人血管内皮抑制素联合化疗治疗晚期恶性肿瘤的临床研究[J].实用临床医药杂志,2011,15(19):43-45,3.
